• 1
    Ferrer J, Villarino MA, Encabo G, et al. Diagnostic utility of CYFRA 21-1, carcinoembryonic antigen, CA 125, neuron specific enolase, and squamous cell antigen level determinations in the serum and pleural fluid of patients with pleural effusions. Cancer. 1999;86:1488-1495.
  • 2
    Marel M, Stastny B, Melinova L, Svandova E, Light RW. Diagnosis of pleural effusions. Experience with clinical studies, 1986 to 1990. Chest. 1995;107:1598-1603.
  • 3
    Maskell NA, Butland RJ; Pleural Diseases Group, Standards of Care Committee, British Thoracic Society. BTS guidelines for the investigation of a unilateral pleural effusion in adults. Thorax. 2003;58(suppl 2):ii8-ii17.
  • 4
    Prakash UB, Reiman HM. Comparison of needle biopsy with cytologic analysis for the evaluation of pleural effusion: analysis of 414 cases. Mayo Clin Proc. 1985;60:158-164.
  • 5
    Miedouge M, Rouzaud P, Salama G, et al. Evaluation of seven tumour markers in pleural fluid for the diagnosis of malignant effusions. Br J Cancer. 1999;81:1059-1065.
  • 6
    Huang WW, Tsao SM, Lai CL, Su CC, Tseng CE. Diagnostic value of Her-2/neu, Cyfra 21-1, and carcinoembryonic antigen levels in malignant pleural effusions of lung adenocarcinoma. Pathology. 2010;42:224-228.
  • 7
    Riantawan P, Sangsayan P, Bangpattanasiri K, Rojanaraweewong P. Limited additive value of pleural fluid carcinoembryonic antigen level in malignant pleural effusion. Respiration. 2000;67:24-29.
  • 8
    Chang SC, Lee LN, Kuo SH, Luh KT, Wu SC. Survival of patients with malignant pleural effusion [in Chinese]. Taiwan Yi Xue Hui Za Zhi. 1987;86:672-678.
  • 9
    Hoffman PC, Mauer AM, Vokes EE. Lung cancer. Lancet. 2000;355:479-485.
  • 10
    Ger LP, Hsu WL, Chen KT, Chen CJ. Risk factors of lung cancer by histological category in Taiwan. Anticancer Res. 1993;13:1491-1500.
  • 11
    Yang SP, Luh KT, Kuo SH, Lin CC. Chronological observation of epidemiological characteristics of lung cancer in Taiwan with etiological consideration–a 30-year consecutive study. Jpn J Clin Oncol. 1984;14:7-19.
  • 12
    Gaspar MJ, De Miguel J, Garcia Diaz JD, Diez M. Clinical utility of a combination of tumour markers in the diagnosis of malignant pleural effusions. Anticancer Res. 2008;28:2947-2952.
  • 13
    Porcel JM, Vives M, Esquerda A, Salud A, Perez B, Rodriguez-Panadero F. Use of a panel of tumor markers (carcinoembryonic antigen, cancer antigen 125, carbohydrate antigen 15-3, and cytokeratin 19 fragments) in pleural fluid for the differential diagnosis of benign and malignant effusions. Chest. 2004;126:1757-1763.
  • 14
    Trape J, Molina R, Sant F. Clinical evaluation of the simultaneous determination of tumor markers in fluid and serum and their ratio in the differential diagnosis of serous effusions. Tumor Biol. 2004;25:276-281.
  • 15
    Krouwer JS. Cumulative distribution analysis graphs–an alternative to ROC curves. Clin Chem. 1987;33:2305-2306.
  • 16
    Hung TL, Chen FF, Liu JM, et al. Clinical evaluation of HER-2/neu protein in malignant pleural effusion-associated lung adenocarcinoma and as a tumor marker in pleural effusion diagnosis. Clin Cancer Res. 2003;9:2605-2612.
  • 17
    Porcel JM, Salud A, Vives M, Esquerda A, Rodriguez-Panadero F. Soluble oncoprotein 185HER-2 in pleural fluid has limited usefulness for the diagnostic evaluation of malignant effusions. Clin Biochem. 2005;38:1031-1033.
  • 18
    Akriviadis EA, Kapnias D, Hadjigavriel M, Mitsiou A, Goulis J. Serum/ascites albumin gradient: its value as a rational approach to the differential diagnosis of ascites. Scand J Gastroenterol. 1996;31:814-817.
  • 19
    Light RW. Diagnostic principles in pleural disease. Eur Respir J. 1997;10:476-481.
  • 20
    Runyon BA, Montano AA, Akriviadis EA, Antillon MR, Irving MA, McHutchison JG. The serum-ascites albumin gradient is superior to the exudate-transudate concept in the differential diagnosis of ascites. Ann Intern Med. 1992;117:215-220.